On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic rhinosinusitis with nasal polyps (CRSwNP).
Both trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score at 52 weeks and a change from baseline in mean nasal obstruction score from weeks 49 to 52.
Also Read: GSK’s Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker’s Lungs, Prepares Competition With Amgen/AstraZeneca’s Drug.
The overall ...